Tag

Wegovy

All articles tagged with #wegovy

health20 hours ago•16 min saved

GLP-1 Drugs Hint at Obesity Decline as Prescriptions Rise

New EPIC Research trackers using COSMOS data show GLP-1 prescriptions have risen fourfold since 2021, while obesity within the dataset declined from 42% to 41%, with GLP-1 users seeing a bigger drop (75% to 69%). While not nationally representative, the trend aligns with CDC estimates and other surveys that show rising GLP-1 use. Barriers like side effects, cost, and insurance limit adoption (about 12% of Americans), and cheaper generics abroad could arrive in five years. If adoption continues, obesity could decline further, though long-term effects remain uncertain.

via Gizmodo|

#epic-research #glp-1s #health

health3 days ago•4 min saved

Wegovy May Carry Higher Risk of Rare Eye Stroke, Study Finds

A FAERS-based analysis of over 30 million adverse-event reports suggests Wegovy has the strongest association with ischemic optic neuropathy among semaglutide drugs, with higher signals in men and at higher Wegovy doses. While cases are rare and causation isn’t proven, researchers call for urgent prospective studies as GLP-1 obesity drugs become more widely used.

via ScienceDaily|

#glp-1 #health #ischemic-optic-neuropathy

health6 days ago•9 min saved

New pill could sustain weight loss after GLP-1 injections

Orforglipron, a once-daily small-molecule pill that targets the GLP-1 system and has FDA approval for obesity, may help people keep most of their weight loss after stopping injections like Wegovy or Mounjaro. In a randomized trial, those who switched to orforglipron regained about 26% of lost weight (vs over 50% on placebo) after 52 weeks, with more than two-fifths maintaining at least 80% of their weight loss and improved health markers such as blood sugar, blood pressure, insulin and cholesterol. The pill could be cheaper and easier to store than peptide injections, but it is not yet licensed in the UK for weight loss, and US monthly costs are roughly $149–$299.

via The Conversation|

#glp-1 #health #obesity

health9 days ago•48 min saved

Life After GLP-1s: Real Experiences With Stopping Weight-Loss Drugs

A BuzzFeed News piece compiles Reddit anecdotes about stopping GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and notes a BMJ meta-analysis finding that people who stop weight loss meds regain weight about four times as fast as those leaving behavioral programs, typically returning to baseline in about 1.7 years. The responses span a spectrum: hunger and food cravings return; some report hair loss or energy dips; many regain weight, but others credit lasting lifestyle changes like mindful eating, calorie tracking, and regular exercise for maintaining weight or easing off gradually. The piece highlights ongoing questions about whether GLP-1s are a temporary boost or a long term tool, and invites more personal experiences.

via BuzzFeed|

#glp-1 #health #mounjaro

business18 days ago•3 min saved

Oral Ozempic and Wegovy Now Eligible for Amazon Same-Day Delivery

Novo Nordisk's oral versions of Ozempic and Wegovy are now available for Amazon same-day delivery, signaling a rapid access expansion after a strong launch that has drawn over a million patients in 16 weeks. The pills—taken daily rather than weekly injections—are expected to boost access to these GLP-1 therapies for diabetes and obesity, with the company citing broader cardiovascular, kidney, and liver benefits and hinting at possible future liver-disease treatments; pricing concessions with the Trump administration aim to broaden affordability, even as short-term effects weigh on the company’s financials.

via New York Post|

#amazon #business #glp-1

business20 days ago•16 min saved

Wegovy-Fueled Q1 Beat Lifts Novo Nordisk's 2026 Outlook

Novo Nordisk beat Q1 estimates on strong Wegovy demand, posting $15.17 billion in revenue and $1.04 in adjusted EPS, and raised its 2026 outlook. The Wegovy pill launch contributed to early sales, with prescriptions surpassing 2 million since launch and more than $2.2 billion in first‑quarter Wegovy pill sales. Management now expects adjusted sales and operating profit to fall 4%–12% for the year, easing fears of a sharp slowdown in the obesity drug market, and the stock moved higher on the report.

via TipRanks|

#business #earnings #novo-nordisk

business21 days ago•5 min saved

Wegovy Drive Lifts Novo Nordisk's 2026 Guidance

Novo Nordisk raised its 2026 guidance after a strong Q1 powered by Wegovy, with U.S. Wegovy prescriptions around 1.3 million and Wegovy sales of 2.26 billion DKK; first-quarter sales rose 32% cc to 96.8 billion DKK and reported operating profit jumped 65%, though adjusted sales fell 4% and adjusted profit fell 6% excluding a $4.2 billion 340B-related adjustment. The company plans to launch Wegovy outside the U.S. in H2 2026, and the stock rose intraday but closed at a new five-year low amid competition in the GLP-1 weight-loss market.

via CNBC|

#business #earnings #glp-1

business22 days ago•6 min saved

Novo's Wegovy Pill Surges Ahead of Lilly's Foundayo in Early Rollout

Novo Nordisk’s Wegovy oral pill has gained strong early momentum since its January launch, aided by aggressive marketing and a lower monthly price, while Lilly’s Foundayo is ramping up more slowly. Telehealth platforms report rapid uptake for Wegovy, and investors are watching first-quarter results and potential international expansion as the GLP-1 pill market expands beyond injections.

via CNBC|

#business #eli-lilly #foundayo

health24 days ago•11 min saved

GLP-1 weight-loss drug Wegovy shows promise in cutting alcohol use among obese patients

A Danish randomized trial of 108 obese adults with alcohol use disorder found that 26 weeks of 2.4 mg semaglutide (Wegovy) reduced heavy drinking days from 17 to about 5 per 30 days and cut total alcohol intake from roughly 2,200 g to 650 g, suggesting GLP-1 therapies could complement treatments for alcohol use disorder alongside weight management.

via The Independent|

#alcohol #alcohol-consumption #health

science25 days ago•22 min saved

Enzyme PapB could boost longevity and potency of Ozempic-like weight‑loss drugs

Scientists at the University of Utah found that the enzyme PapB can macrocyclize GLP-1–like drug peptides, increasing their stability and duration in the body, potentially making Ozempic/Wegovy‑type weight‑loss drugs more potent and longer‑lasting.

via New York Post|

#glp-1 #macrocyclization #ozempic

health27 days ago•54 min saved

Eye-stroke signals surface with Wegovy, but the risk remains very low and unproven

A British Journal of Ophthalmology study analyzed FDA adverse-event reports and found ischemic optic neuropathy (ION) in fewer than 1% of Wegovy users (28 of 3,070 reports) versus 47 of 20,608 for Ozempic, suggesting a possible Wegovy-specific signal but not proving causation. The data come from voluntary reports and don’t establish true risk; experts say the overall risk is very low and Wegovy’s benefits for weight management likely outweigh this potential issue. Regulators advise urgent medical care if eyesight worsens quickly, and Rybelsus showed no notable link in the study; dose differences remain unproven as a factor.

via Live Science|

#eye-stroke #health #ischemic-optic-neuropathy

health28 days ago•3 min saved

Joint GLP-1 Hint Opens Door to New Arthritis Treatments

Researchers found GLP-1 in the synovial fluid of arthritis patients and observed that joint levels track with blood levels. While high-dose GLP-1 medications could potentially modulate joint inflammation beyond weight loss, this has not been proven for arthritis. More clinical studies are needed to determine if GLP-1–based therapies can reach the joints in sufficient quantities and actually reduce inflammation, but the finding lays groundwork for new treatment avenues.

via SciTechDaily|

#arthritis #glp-1 #health

markets1 month ago•3 min saved

Lilly Obesity Drugs Lag Wegovy in Early Prescription Data, Weighing on Stock

Premarket, Eli Lilly shares fell after IQVIA data cited by Bloomberg showed Lilly’s obesity drugs Foundayo (oral) and Zepbound trailed Novo Nordisk’s Wegovy in weekly prescriptions; Zepbound fell about 2% week over week while Wegovy rose about 7% in the same period, and Foundayo posted 3,707 prescriptions in its first full week versus Wegovy’s roughly 18,410 in its first full week; analysts caution that one week of data isn’t definitive, but weak early momentum could pressure Lilly stock if the trend persists.

via Seeking Alpha|

#eli-lilly #foundayo #markets

health1 month ago•11 min saved

Secret GLP-1 Weight-Loss: Why Some Women Hide Medication From Partners

Some women using GLP-1 weight-loss meds like Wegovy keep their use secret from partners to avoid lectures and stigma, a pattern highlighted by personal stories and a Reddit thread. Telemedicine can make obtaining prescriptions easier, but hiding meds can complicate medical care and complicate conversations about health goals. Experts suggest planning conversations with partners and being honest about motivations, while recognizing the broader issues of weight stigma and autonomy in treatment.

via SELF Magazine|

#glp-1 #health #relationships

health1 month ago•176 min saved

GLP-1 Drugs Show Health Benefits Beyond Weight Loss, From Liver to Heart

New findings indicate GLP-1 drugs like Wegovy and Zepbound can improve liver health and reduce inflammation even without weight loss, with trials showing cardiovascular and liver benefits beyond weight reduction; this could push insurers to rethink coverage criteria, though much of the mechanistic support comes from animal studies and human relevance remains under study.

via CNN|

#glp-1 #health #liver-health